Scribd Logo
Hochladen

Willkommen bei Scribd!

  • Merck & Co

    Hochgeladen von

    Asha Briyanti
    19 Ansichten1 Seite
    Summary of case “Merck & Company: Evaluating a Drug Licensing Opportunity?” Merck & Co., Inc. was a global-research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products. The company earned $5.9 billion on 1999 sales of $32.7 billion, 20% increase from 1998 and already had launched 15 new product. Their most popular drugs, Vasotec, Mevacor, Prinivil and Pepcid generated $5.7 billion in worldwide sales.

    Copyright

    © © All Rights Reserved

    Verfügbare Formate

    PDF, TXT oder online auf Scribd lesen

    Stufen Sie dieses Dokument als nützlich ein?

    Sind diese Inhalte unangemessen?

    Dieses Dokument melden
    Summary of case “Merck & Company: Evaluating a Drug Licensing Opportunity?” Merck & Co., Inc. was a global-research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products. The company earned $5.9 billion on 1999 sales of $32.7 billion, 20% increase from 1998 and already had launched 15 new product. Their most popular drugs, Vasotec, Mevacor, Prinivil and Pepcid generated $5.7 billion in worldwide sales.

    Copyright:

    © All Rights Reserved
    Als PDF, TXT herunterladen oder online auf Scribd lesen
    Markieren Sie unangemessene Inhalte
    19 Ansichten1 Seite

    Merck & Co

    Hochgeladen von

    Asha Briyanti
    Summary of case “Merck & Company: Evaluating a Drug Licensing Opportunity?” Merck & Co., Inc. was a global-research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products. The company earned $5.9 billion on 1999 sales of $32.7 billion, 20% increase from 1998 and already had launched 15 new product. Their most popular drugs, Vasotec, Mevacor, Prinivil and Pepcid generated $5.7 billion in worldwide sales.

    Copyright:

    © All Rights Reserved
    Als PDF, TXT herunterladen oder online auf Scribd lesen
    Markieren Sie unangemessene Inhalte
    von 1

    For Evaluation Only

    DECISION MAKING AND NEGOTIATION INDIVIDUAL ASSIGNMENT


    ASHA BRIYANTI (29317349); Ahmad Fathoriq (29317383) Gheo Olivero 29317467 ; Nabilla Sarah Permana (23917406) Siska Yenny (29317321)

    1 TreePlan Trial Version, For Evaluation Only 85% www.TreePlan.com Launching Cash Flow Probability Expected Value
    Succeed
    10% - 520 1.200 680 5,10% 34,68
    Depression - 250 - 520
    2
    - 200 - 270 15%
    Failure
    - 270 - - 270 0,90% - 2,43
    - - 270

    75%
    Succeed
    15% - 320 345 25 6,75% 1,69
    Weight loss - 100 - 320
    2
    - 150 - 220 25%
    Failure
    - 220 - - 220 2,25% - 4,95
    - - 220

    15%
    D
    Phase II - 820 1.200 380 0,45% 1,71
    4 - 250 - 820
    - -70
    5%
    WL
    5% - 670 345 - 325 0,15% - 0,49
    D & WL - 100 - 670
    4
    - 500 -570 70%
    D & WL
    - 970 2.250 1.280 2,10% 26,88
    60% - 400 - 970
    Succeed
    1 10%
    - 40 - 70 Failure -
    - 570 - 570 0,30% - 1,71
    - - 570

    70%
    100% Failure
    Phase I - 70
    - - 70
    - -54

    Failure
    - 70 - 70 42% - 29,40
    - - 70
    Licensing
    40%
    - 30 -54 Failure
    - 30 - 30 40% - 12,00
    - - 30

    0%
    2 Not enter phase I
    0 - 30
    - - 30
    2

    3 Not Licensing
    -
    - - For Evaluation Only 880,000 1,000 13,980

    TreePlan Trial, For Evaluation Only www.TreePlan.com

    Das könnte Ihnen auch gefallen